Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: A single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers

Clinical Therapeutics

Volumn 32, Issue 3, 2010, Pages 588-596

  Iqbal, Muzaffar ^a   Khuroo, Arshad ^b   Batolar, Lakhvinder S ^a   Tandon, Monika ^c   Monif, Tausif ^b   Sharma, P L ^a  

^a HAMDARD UNIVERSITY   (India)

^b Ranbaxy Research Laboratory   (India)

^c FORTIS HOSPITAL   (India)

Author keywords

Bioequivalence; HPLC method; Pharmacokinetics; Valsartan

Indexed keywords

GENERIC DRUG; UNCLASSIFIED DRUG; VALENT; VALSARTAN; VALZAAR;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INDIAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUGS, GENERIC; HALF-LIFE; HUMANS; INDIA; LEAST-SQUARES ANALYSIS; MALE; TABLETS; TETRAZOLES; THERAPEUTIC EQUIVALENCY; VALINE; YOUNG ADULT;

EID: 77951950634     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.03.004     Document Type: Article

References (24)

1. Haas JS, Phillips KA, Gerstenberger EP, Seger AC Potential savings from substituting generic drugs for brand-name drugs: Medical expenditure panel survey, 1997-2000. Ann Intern Med. 2005, 142:891-897.
2. Pitt B Generic drugs in cardiology: Will they reduce health care costs?. J Am Coll Cardiol. 2004, 44:10-13.
3. Marriott JF BNF recommendations of substitution: Are they followed in practice?. Pharm J. 1999, 263:289-292.
4. Snow Jr DB Maximising generic utilisation: The power of pharmacy benefit management. J Gen Med. 2007, 5:27-38.
5. Meredith PA Generic drugs. Therapeutic equivalence. Drug Saf. 1996, 15:223-242.
6. Spino M, Tsang Y, Pop R Dissolution and in vivo evidence of differences in reference products: Impact on development of generic drugs. Eur J Drug Metab Pharmacokinet. 2000, 25:18-24.
7. Pincock S WHO tries to tackle problem of counterfeit medicines in Asia. BMJ. 2003, 327:1126.
8. Khan AY, Ghilzai NM Counterfeit and substandard quality of drugs: The need for an effective and stringent regulatory control in India and other developing countries. Ind J Pharmacol. 2007, 39:206-207.
9. Dos Reis Serra CH, Mori Koono EE, Kano EK, et al. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: An openlabel, randomized, single-dose, two-way crossover study. Clin Ther. 2008, 30:902-908.
10. Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products-general considerations US Dept of Health and Human Services (HHS), Food and Drug Administration (FDA)Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Accessed November 13, 2008. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsar eDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplication ANDAGenerics/UCM154838.pdf.
11. Guidelines for bioavailability & bioequivalence studies Central Drugs Standard Control Organization, Directorate General of Health ServicesDirectorate General of Health Services, Ministry of Health & Family WelfareMinistry of Health & Family Welfare, Accessed November 13, 2008. http://www.cdsco.nic.in/htmL/BE%20Guidelines%20Draft%20Ver10%20March%201 6,%2005.pdf.
12. Al-Jazairi AS, Bhareth S, Eqtefan IS, Al-Suwayeh SA Brand and generic medications: Are they interchangeable?. Ann Saudi Med. 2008, 28:33-41.
13. Nakai K, Fujita M, Ogata H International harmonisation of bioequivalence studies and issues shared in common. Yakugaku Zasshi. 2000, 120:1193-1200.
14. Markham A, Goa KL Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997, 54:299-311.
15. Diovan [prescribing information] 2007, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
16. Colussi DM, Parisot C, Rossolino ML, et al. Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist. J Clin Pharmacol. 1997, 37:214-221.
17. Flesch G, Müller P, Lloyd P Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol. 1997, 52:115-120.
18. UK Summary of Product Characteristics: Diovan Accessed May 13, 2009. http://emc.medicines.org.uk/document.aspx?documentId=1279.
19. Müller P, Flesch G, de Gasparo M, et al. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol. 1997, 52:441-449.
20. Sioufi A, Marfil F, Jaouen A, et al. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos. 1998, 19:237-244.
21. Séchaud R, Graf P, Bigler H, et al. Bioequivalence study of a valsartan tablet and a capsule formulation after single dosing in healthy volunteers using a replicated crossover design. Int J Clin Pharmacol Ther. 2002, 40:35-40.
22. Pérez M, Cardenas W, Quim GR, et al. A comparative, cross-over, double blind, randomized study for bioequivalence assessment between two formulations of valsartan capsules vs tablets. Revista Colombia Médica. 2006, 37:114-120.
23. Franco Spínola AC, Almeida S, Filipe A, et al. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions. Clin Ther. 2009, 31:1992-2001.
24. Guidance for Industry. Bioanalytical method validation US Dept of Health and Human Services (HHS), Food and Drug Administration (FDA)Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM)Center for Veterinary Medicine (CVM), Accessed November 13, 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/UCM070107.pdf.